Adicet Bio (ACET)
Develops off-the-shelf gamma delta CAR-T cell therapies for autoimmune disease and cancer.
Something off on this page? Send us feedback.
Develops allogeneic gamma delta CAR-T cell therapies in clinical development, centered on prula-cel for autoimmune disease and ADI-212 for prostate cancer. The Boston-based company focuses its resources on these programs after discontinuing ADI-270.
Built around an allogeneic gamma delta CAR-T platform, the company develops off-the-shelf cell therapies for autoimmune disease and cancer. The cells are engineered with chimeric antigen receptors. Its current pipeline centers on prulacabtagene leucel, or prula-cel, for autoimmune disease and ADI-212 for metastatic castration-resistant prostate cancer.
Based in Boston, the clinical-stage business concentrated resources on those two programs after discontinuing ADI-270. That pipeline reset narrowed work to autoimmune disease and prostate cancer. Prula-cel and ADI-212 remain development programs rather than approved products, so the business depends on clinical progress for its prioritized candidates.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | H.C. Wainwright | Target | Target: $38 | Target: $27 |
| Jan 6, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: — | Target: $18 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $118.2M · Total debt $12.9M · Total assets $148.2M · Shareholders' equity $120.1M
- Revenue
- $0
- Operating income
- −$22.3M
- Net income
- −$21.4M
No dividends on record.
| Institutions | 65.27% | 6.11M shares | |
|---|---|---|---|
| 59 holders · as of Jun 30, 2026 | |||
| Insiders | 0.32% | 29.6K shares | |
| 9 holders · as of Jan 27, 2026 | |||
| Other | 34.41% | 3.22M shares | |
| remainder | |||
9.36M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 9.96% | 932,624 | as of Jun 30, 2026 |
Orbimed Advisors LLCInstitution | 9.02% | 844,787 | as of Jun 30, 2026 |
Franklin Resources IncInstitution | 6.69% | 626,571 | as of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 4.62% | 432,738 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.67% | 343,228 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 18, 2026 | Ra Capital Management, L.P. | 10 percent owner | +74,577 | $7.04 |
| Feb 19, 2026 | Ra Capital Management, L.P. | 10 percent owner | +74,268 | $7.21 |
| Feb 20, 2026 | Ra Capital Management, L.P. | 10 percent owner | +74,751 | $7.27 |
| Apr 8, 2026 | Orbimed Advisors LLC | 10 percent owner | −72,939 | $6.42 |
| Apr 7, 2026 | Orbimed Advisors LLC | 10 percent owner | −31,719 | $6.52 |
- Allogene Therapeutics
Allogeneic CD19/CD70 CAR-T in autoimmune disease
- Fate
Off-the-shelf CD19 CAR-T for autoimmune disease
- Nkarta
Allogeneic CD19 CAR-NK for autoimmune disease
- Cabaletta Bio
Autologous CD19 CAR-T across autoimmune diseases
- Caribou Biosciences
Allogeneic CAR-T programs for B-cell malignancies
- Cellectis (ADR)
Gene-edited allogeneic CAR-T for B-cell cancers
- IN8bio
Gamma-delta T-cell therapies for cancer and autoimmunity
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Adicet Bio | $9.23 | +3.30% | $83.5M | — | — | — | — |
| Allogene Therapeutics | $1.71 | +0.89% | $583.3M | — | — | 125.7 | — |
| Fate | $2.59 | +2.17% | $294.9M | — | — | 45.4 | +9.2% |
| Nkarta | $2.89 | +0.34% | $206.1M | — | — | — | — |
| Cabaletta Bio | $2.54 | +3.25% | $401.1M | — | — | — | — |
| Caribou Biosciences | $1.34 | +2.75% | $128.9M | — | — | 12.8 | −43.8% |
| Cellectis (ADR) | $1.59 | +4.97% | $151.6M | — | — | 2.7 | −59.2% |
| IN8bio | $1.15 | +8.49% | $10.2M | — | — | — | — |
| Median | — | — | 29.1 | −43.8% |